世界の眼科治療薬市場2023年-2027年

【英語タイトル】Global Ophthalmology Therapeutics Market 2023-2027

Technavioが出版した調査資料(IRTNTR40882-23)・商品コード:IRTNTR40882-23
・発行会社(調査会社):Technavio
・発行日:2022年12月29日
・ページ数:170
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:北米、ヨーロッパ、アジア、その他地域
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥370,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Technavio社の本調査レポートによると、世界の眼科治療薬市場規模が2022年から2027年まで年平均6.25%成長し、157.2億ドルに達すると予測されています。本書では、眼科治療薬の世界市場を調査対象とし、エグゼクティブサマリー、市場状況、市場規模予測、過去の市場規模、ファイブフォース分析、製品別(網膜疾患、緑内障、ドライアイ、眼感染症&眼炎症、その他)分析、種類別(処方薬、OTC医薬品)分析、顧客状況、地域別状況(北米、ヨーロッパ、アジア太平洋、その他地域、アメリカ、ドイツ、イギリス、フランス、日本)分析、推進要因・課題・動向、企業状況、企業分析などの項目を掲載しています。なお、本書には、主要企業としてAbbVie Inc.、Adrif Vision、Aldeyra Therapeutics Inc.、Bausch Health Co Inc.、Bayer AG、Eyeris Vision Care Pvt. Ltd.、F. Hoffmann La Roche Ltd.、Grevis Pharmaceuticals Pvt. Ltd.、Novartis AG、Ocular Therapeutix Inc.、Otsuka Pharmaceutical Co. Ltd.、Oxurion NV、Pfizer Inc.、Regeneron Pharmaceuticals Inc.、Santen Pharmaceutical Co. Ltd.、Sun Pharmaceutical Industries Ltd.、Swissvision、Teva Pharmaceutical Industries Ltd.、Vee Remedies、Visufarmaなどの企業情報が含まれています。
・エグゼクティブサマリー
・市場状況
・市場規模予測
・過去の市場規模
・ファイブフォース分析
・世界の眼科治療薬市場規模:製品別
- 網膜疾患治療薬の市場規模
- 緑内障治療薬の市場規模
- ドライアイ治療薬の市場規模
- 眼感染症&眼炎症治療薬の市場規模
- その他製品の市場規模
・世界の眼科治療薬市場規模:種類別
- 処方薬の市場規模
- OTC医薬品の市場規模
・顧客状況
・世界の眼科治療薬市場規模:地域別
- 北米の眼科治療薬市場規模
- ヨーロッパの眼科治療薬市場規模
- アジア太平洋の眼科治療薬市場規模
- その他地域の眼科治療薬市場規模
- アメリカの眼科治療薬市場規模
- ドイツの眼科治療薬市場規模
- イギリスの眼科治療薬市場規模
- フランスの眼科治療薬市場規模
- 日本の眼科治療薬市場規模
・推進要因・課題・動向
・企業状況
・企業分析

Technavio社は、利益、価格、競争、プロモーションなどの主要なパラメーターを分析することにより、また複数のソースからのデータを調査、統合、および合計することにより、市場の詳細な全体像を提示します。主要産業のインフルエンサーを特定することにより、さまざまな市場の側面を提示します。提示されたデータは包括的​​で信頼性が高く、一次および二次の広範な調査の結果です。Technavio社の市場調査報告書は、正確な市場の成長を予測するための定性的および定量的調査を使用し、完全な競争状況と詳細なベンダー選択方法と分析を提供します。

眼科治療薬の世界市場 2023-2027

Technavio社は、眼科治療薬市場をモニターしており、2022年から2027年にかけて157.2億ドルの成長が予測され、予測期間中のCAGRは6.25%で加速すると予測しています。当レポートでは、眼科治療薬市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題に加え、約25のベンダーを網羅したベンダー分析も提供しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。眼疾患の有病率の増加、新規治療薬の承認と強力な医薬品パイプライン、抗VEGF阻害剤の堅調な取り込みが市場を牽引しています。

Technavio社の眼科治療薬市場は以下のように分類されています:

・製品別:
- 網膜疾患
- 緑内障
- ドライアイ
- 眼感染症・眼炎症
- その他の治療薬

・タイプ別:
- 処方薬
- 一般用医薬品

・地域別:
- 北米
- ヨーロッパ
- アジア
- その他の地域(ROW)

本調査では、今後数年間における眼科治療薬市場の成長を促進する主な要因の1つとして、新規ドラッグデリバリーシステムの開発を挙げています。また、戦略的提携の増加や遺伝子治療製品に関する研究の増加は、市場の大きな需要につながるでしょう。

Technavio社は、複数の情報源からのデータを調査、合成、要約し、主要パラメータの分析によって、市場の詳細な姿を提示します。

当レポートでは、眼科治療薬市場について以下の分野を扱っています:
- 眼科治療薬市場のサイジング
- 眼科治療薬市場の予測
- 眼科治療薬市場の産業分析

Technavio社の確実なベンダー分析は、クライアントが市場でのポジションを向上できるように設計されており、これに沿って本レポートには、AbbVie Inc., Adrif Vision, Aldeyra Therapeutics Inc., Bausch Health Co Inc., Bayer AG, Eyeris Vision Care Pvt. Ltd., F. Hoffmann La Roche Ltd., Grevis Pharmaceuticals Pvt. Ltd., Novartis AG, Ocular Therapeutix Inc., Otsuka Pharmaceutical Co. Ltd., Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Swissvision, Teva Pharmaceutical Industries Ltd., Vee Remedies, and Visufarmaなどの企業情報が含まれています。また、眼科治療薬市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートでは、主要ベンダーの分析に加え、包括的な市場およびベンダーの状況を掲載しています。

Technavioは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、要約する方法で、市場の詳細な姿を提示します。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示します。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ billion)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ billion)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global ophthalmology therapeutics market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global ophthalmology therapeutics market 2017 – 2021 ($ billion)
o 4.2 Product Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Product Segment 2017 – 2021 ($ billion)
o 4.3 Type Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Type Segment 2017 – 2021 ($ billion)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ billion)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ billion)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Product
o 6.1 Market segments
o Exhibit 30: Chart on Product – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Product – Market share 2022-2027 (%)
o 6.2 Comparison by Product
o Exhibit 32: Chart on Comparison by Product
o Exhibit 33: Data Table on Comparison by Product
o 6.3 Retinal disorder therapeutics – Market size and forecast 2022-2027
o Exhibit 34: Chart on Retinal disorder therapeutics – Market size and forecast 2022-2027 ($ billion)
o Exhibit 35: Data Table on Retinal disorder therapeutics – Market size and forecast 2022-2027 ($ billion)
o Exhibit 36: Chart on Retinal disorder therapeutics – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Retinal disorder therapeutics – Year-over-year growth 2022-2027 (%)
o 6.4 Glaucoma therapeutics – Market size and forecast 2022-2027
o Exhibit 38: Chart on Glaucoma therapeutics – Market size and forecast 2022-2027 ($ billion)
o Exhibit 39: Data Table on Glaucoma therapeutics – Market size and forecast 2022-2027 ($ billion)
o Exhibit 40: Chart on Glaucoma therapeutics – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Glaucoma therapeutics – Year-over-year growth 2022-2027 (%)
o 6.5 Dry eye disease therapeutics – Market size and forecast 2022-2027
o Exhibit 42: Chart on Dry eye disease therapeutics – Market size and forecast 2022-2027 ($ billion)
o Exhibit 43: Data Table on Dry eye disease therapeutics – Market size and forecast 2022-2027 ($ billion)
o Exhibit 44: Chart on Dry eye disease therapeutics – Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on Dry eye disease therapeutics – Year-over-year growth 2022-2027 (%)
o 6.6 Eye infections and inflammation therapeutics – Market size and forecast 2022-2027
o Exhibit 46: Chart on Eye infections and inflammation therapeutics – Market size and forecast 2022-2027 ($ billion)
o Exhibit 47: Data Table on Eye infections and inflammation therapeutics – Market size and forecast 2022-2027 ($ billion)
o Exhibit 48: Chart on Eye infections and inflammation therapeutics – Year-over-year growth 2022-2027 (%)
o Exhibit 49: Data Table on Eye infections and inflammation therapeutics – Year-over-year growth 2022-2027 (%)
o 6.7 Other therapeutics – Market size and forecast 2022-2027
o Exhibit 50: Chart on Other therapeutics – Market size and forecast 2022-2027 ($ billion)
o Exhibit 51: Data Table on Other therapeutics – Market size and forecast 2022-2027 ($ billion)
o Exhibit 52: Chart on Other therapeutics – Year-over-year growth 2022-2027 (%)
o Exhibit 53: Data Table on Other therapeutics – Year-over-year growth 2022-2027 (%)
o 6.8 Market opportunity by Product
o Exhibit 54: Market opportunity by Product ($ billion)
• 7 Market Segmentation by Type
o 7.1 Market segments
o Exhibit 55: Chart on Type – Market share 2022-2027 (%)
o Exhibit 56: Data Table on Type – Market share 2022-2027 (%)
o 7.2 Comparison by Type
o Exhibit 57: Chart on Comparison by Type
o Exhibit 58: Data Table on Comparison by Type
o 7.3 Prescription drugs – Market size and forecast 2022-2027
o Exhibit 59: Chart on Prescription drugs – Market size and forecast 2022-2027 ($ billion)
o Exhibit 60: Data Table on Prescription drugs – Market size and forecast 2022-2027 ($ billion)
o Exhibit 61: Chart on Prescription drugs – Year-over-year growth 2022-2027 (%)
o Exhibit 62: Data Table on Prescription drugs – Year-over-year growth 2022-2027 (%)
o 7.4 OTC drugs – Market size and forecast 2022-2027
o Exhibit 63: Chart on OTC drugs – Market size and forecast 2022-2027 ($ billion)
o Exhibit 64: Data Table on OTC drugs – Market size and forecast 2022-2027 ($ billion)
o Exhibit 65: Chart on OTC drugs – Year-over-year growth 2022-2027 (%)
o Exhibit 66: Data Table on OTC drugs – Year-over-year growth 2022-2027 (%)
o 7.5 Market opportunity by Type
o Exhibit 67: Market opportunity by Type ($ billion)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 69: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 70: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 71: Chart on Geographic comparison
o Exhibit 72: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 73: Chart on North America – Market size and forecast 2022-2027 ($ billion)
o Exhibit 74: Data Table on North America – Market size and forecast 2022-2027 ($ billion)
o Exhibit 75: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 77: Chart on Europe – Market size and forecast 2022-2027 ($ billion)
o Exhibit 78: Data Table on Europe – Market size and forecast 2022-2027 ($ billion)
o Exhibit 79: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 81: Chart on Asia – Market size and forecast 2022-2027 ($ billion)
o Exhibit 82: Data Table on Asia – Market size and forecast 2022-2027 ($ billion)
o Exhibit 83: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 85: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ billion)
o Exhibit 86: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ billion)
o Exhibit 87: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 89: Chart on US – Market size and forecast 2022-2027 ($ billion)
o Exhibit 90: Data Table on US – Market size and forecast 2022-2027 ($ billion)
o Exhibit 91: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Germany – Market size and forecast 2022-2027
o Exhibit 93: Chart on Germany – Market size and forecast 2022-2027 ($ billion)
o Exhibit 94: Data Table on Germany – Market size and forecast 2022-2027 ($ billion)
o Exhibit 95: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.9 UK – Market size and forecast 2022-2027
o Exhibit 97: Chart on UK – Market size and forecast 2022-2027 ($ billion)
o Exhibit 98: Data Table on UK – Market size and forecast 2022-2027 ($ billion)
o Exhibit 99: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 100: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.10 France – Market size and forecast 2022-2027
o Exhibit 101: Chart on France – Market size and forecast 2022-2027 ($ billion)
o Exhibit 102: Data Table on France – Market size and forecast 2022-2027 ($ billion)
o Exhibit 103: Chart on France – Year-over-year growth 2022-2027 (%)
o Exhibit 104: Data Table on France – Year-over-year growth 2022-2027 (%)
o 9.11 Japan – Market size and forecast 2022-2027
o Exhibit 105: Chart on Japan – Market size and forecast 2022-2027 ($ billion)
o Exhibit 106: Data Table on Japan – Market size and forecast 2022-2027 ($ billion)
o Exhibit 107: Chart on Japan – Year-over-year growth 2022-2027 (%)
o Exhibit 108: Data Table on Japan – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 109: Market opportunity By Geographical Landscape ($ billion)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 110: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 111: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 112: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 113: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 114: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 115: Matrix on vendor position and classification
o 12.3 AbbVie Inc.
o Exhibit 116: AbbVie Inc. – Overview
o Exhibit 117: AbbVie Inc. – Product / Service
o Exhibit 118: AbbVie Inc. – Key news
o Exhibit 119: AbbVie Inc. – Key offerings
o 12.4 Aldeyra Therapeutics Inc.
o Exhibit 120: Aldeyra Therapeutics Inc. – Overview
o Exhibit 121: Aldeyra Therapeutics Inc. – Product / Service
o Exhibit 122: Aldeyra Therapeutics Inc. – Key offerings
o 12.5 Bausch Health Co Inc.
o Exhibit 123: Bausch Health Co Inc. – Overview
o Exhibit 124: Bausch Health Co Inc. – Business segments
o Exhibit 125: Bausch Health Co Inc. – Key news
o Exhibit 126: Bausch Health Co Inc. – Key offerings
o Exhibit 127: Bausch Health Co Inc. – Segment focus
o 12.6 Bayer AG
o Exhibit 128: Bayer AG – Overview
o Exhibit 129: Bayer AG – Business segments
o Exhibit 130: Bayer AG – Key news
o Exhibit 131: Bayer AG – Key offerings
o Exhibit 132: Bayer AG – Segment focus
o 12.7 F. Hoffmann La Roche Ltd.
o Exhibit 133: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 134: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 135: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 136: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 137: F. Hoffmann La Roche Ltd. – Segment focus
o 12.8 Novartis AG
o Exhibit 138: Novartis AG – Overview
o Exhibit 139: Novartis AG – Business segments
o Exhibit 140: Novartis AG – Key offerings
o Exhibit 141: Novartis AG – Segment focus
o 12.9 Ocular Therapeutix Inc.
o Exhibit 142: Ocular Therapeutix Inc. – Overview
o Exhibit 143: Ocular Therapeutix Inc. – Product / Service
o Exhibit 144: Ocular Therapeutix Inc. – Key offerings
o 12.10 Otsuka Pharmaceutical Co. Ltd.
o Exhibit 145: Otsuka Pharmaceutical Co. Ltd. – Overview
o Exhibit 146: Otsuka Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 147: Otsuka Pharmaceutical Co. Ltd. – Key offerings
o 12.11 Oxurion NV
o Exhibit 148: Oxurion NV – Overview
o Exhibit 149: Oxurion NV – Product / Service
o Exhibit 150: Oxurion NV – Key offerings
o 12.12 Pfizer Inc.
o Exhibit 151: Pfizer Inc. – Overview
o Exhibit 152: Pfizer Inc. – Product / Service
o Exhibit 153: Pfizer Inc. – Key news
o Exhibit 154: Pfizer Inc. – Key offerings
o 12.13 Regeneron Pharmaceuticals Inc.
o Exhibit 155: Regeneron Pharmaceuticals Inc. – Overview
o Exhibit 156: Regeneron Pharmaceuticals Inc. – Product / Service
o Exhibit 157: Regeneron Pharmaceuticals Inc. – Key offerings
o 12.14 Santen Pharmaceutical Co. Ltd.
o Exhibit 158: Santen Pharmaceutical Co. Ltd. – Overview
o Exhibit 159: Santen Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 160: Santen Pharmaceutical Co. Ltd. – Key offerings
o 12.15 Sun Pharmaceutical Industries Ltd.
o Exhibit 161: Sun Pharmaceutical Industries Ltd. – Overview
o Exhibit 162: Sun Pharmaceutical Industries Ltd. – Product / Service
o Exhibit 163: Sun Pharmaceutical Industries Ltd. – Key offerings
o 12.16 Teva Pharmaceutical Industries Ltd.
o Exhibit 164: Teva Pharmaceutical Industries Ltd. – Overview
o Exhibit 165: Teva Pharmaceutical Industries Ltd. – Business segments
o Exhibit 166: Teva Pharmaceutical Industries Ltd. – Key news
o Exhibit 167: Teva Pharmaceutical Industries Ltd. – Key offerings
o Exhibit 168: Teva Pharmaceutical Industries Ltd. – Segment focus
o 12.17 Visufarma
o Exhibit 169: Visufarma – Overview
o Exhibit 170: Visufarma – Product / Service
o Exhibit 171: Visufarma – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 172: Inclusions checklist
o Exhibit 173: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 174: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 175: Research methodology
o Exhibit 176: Validation techniques employed for market sizing
o Exhibit 177: Information sources
o 13.5 List of abbreviations
o Exhibit 178: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Product
Exhibits6: Executive Summary – Chart on Market Segmentation by Type
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ billion)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ billion)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global ophthalmology therapeutics market 2017 – 2021 ($ billion)
Exhibits19: Historic Market Size – Product Segment 2017 – 2021 ($ billion)
Exhibits20: Historic Market Size – Type Segment 2017 – 2021 ($ billion)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ billion)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ billion)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Product – Market share 2022-2027 (%)
Exhibits31: Data Table on Product – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Product
Exhibits33: Data Table on Comparison by Product
Exhibits34: Chart on Retinal disorder therapeutics – Market size and forecast 2022-2027 ($ billion)
Exhibits35: Data Table on Retinal disorder therapeutics – Market size and forecast 2022-2027 ($ billion)
Exhibits36: Chart on Retinal disorder therapeutics – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Retinal disorder therapeutics – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Glaucoma therapeutics – Market size and forecast 2022-2027 ($ billion)
Exhibits39: Data Table on Glaucoma therapeutics – Market size and forecast 2022-2027 ($ billion)
Exhibits40: Chart on Glaucoma therapeutics – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Glaucoma therapeutics – Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on Dry eye disease therapeutics – Market size and forecast 2022-2027 ($ billion)
Exhibits43: Data Table on Dry eye disease therapeutics – Market size and forecast 2022-2027 ($ billion)
Exhibits44: Chart on Dry eye disease therapeutics – Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on Dry eye disease therapeutics – Year-over-year growth 2022-2027 (%)
Exhibits46: Chart on Eye infections and inflammation therapeutics – Market size and forecast 2022-2027 ($ billion)
Exhibits47: Data Table on Eye infections and inflammation therapeutics – Market size and forecast 2022-2027 ($ billion)
Exhibits48: Chart on Eye infections and inflammation therapeutics – Year-over-year growth 2022-2027 (%)
Exhibits49: Data Table on Eye infections and inflammation therapeutics – Year-over-year growth 2022-2027 (%)
Exhibits50: Chart on Other therapeutics – Market size and forecast 2022-2027 ($ billion)
Exhibits51: Data Table on Other therapeutics – Market size and forecast 2022-2027 ($ billion)
Exhibits52: Chart on Other therapeutics – Year-over-year growth 2022-2027 (%)
Exhibits53: Data Table on Other therapeutics – Year-over-year growth 2022-2027 (%)
Exhibits54: Market opportunity by Product ($ billion)
Exhibits55: Chart on Type – Market share 2022-2027 (%)
Exhibits56: Data Table on Type – Market share 2022-2027 (%)
Exhibits57: Chart on Comparison by Type
Exhibits58: Data Table on Comparison by Type
Exhibits59: Chart on Prescription drugs – Market size and forecast 2022-2027 ($ billion)
Exhibits60: Data Table on Prescription drugs – Market size and forecast 2022-2027 ($ billion)
Exhibits61: Chart on Prescription drugs – Year-over-year growth 2022-2027 (%)
Exhibits62: Data Table on Prescription drugs – Year-over-year growth 2022-2027 (%)
Exhibits63: Chart on OTC drugs – Market size and forecast 2022-2027 ($ billion)
Exhibits64: Data Table on OTC drugs – Market size and forecast 2022-2027 ($ billion)
Exhibits65: Chart on OTC drugs – Year-over-year growth 2022-2027 (%)
Exhibits66: Data Table on OTC drugs – Year-over-year growth 2022-2027 (%)
Exhibits67: Market opportunity by Type ($ billion)
Exhibits68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits69: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits70: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits71: Chart on Geographic comparison
Exhibits72: Data Table on Geographic comparison
Exhibits73: Chart on North America – Market size and forecast 2022-2027 ($ billion)
Exhibits74: Data Table on North America – Market size and forecast 2022-2027 ($ billion)
Exhibits75: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on Europe – Market size and forecast 2022-2027 ($ billion)
Exhibits78: Data Table on Europe – Market size and forecast 2022-2027 ($ billion)
Exhibits79: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on Asia – Market size and forecast 2022-2027 ($ billion)
Exhibits82: Data Table on Asia – Market size and forecast 2022-2027 ($ billion)
Exhibits83: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ billion)
Exhibits86: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ billion)
Exhibits87: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on US – Market size and forecast 2022-2027 ($ billion)
Exhibits90: Data Table on US – Market size and forecast 2022-2027 ($ billion)
Exhibits91: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on Germany – Market size and forecast 2022-2027 ($ billion)
Exhibits94: Data Table on Germany – Market size and forecast 2022-2027 ($ billion)
Exhibits95: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits97: Chart on UK – Market size and forecast 2022-2027 ($ billion)
Exhibits98: Data Table on UK – Market size and forecast 2022-2027 ($ billion)
Exhibits99: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits100: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits101: Chart on France – Market size and forecast 2022-2027 ($ billion)
Exhibits102: Data Table on France – Market size and forecast 2022-2027 ($ billion)
Exhibits103: Chart on France – Year-over-year growth 2022-2027 (%)
Exhibits104: Data Table on France – Year-over-year growth 2022-2027 (%)
Exhibits105: Chart on Japan – Market size and forecast 2022-2027 ($ billion)
Exhibits106: Data Table on Japan – Market size and forecast 2022-2027 ($ billion)
Exhibits107: Chart on Japan – Year-over-year growth 2022-2027 (%)
Exhibits108: Data Table on Japan – Year-over-year growth 2022-2027 (%)
Exhibits109: Market opportunity By Geographical Landscape ($ billion)
Exhibits110: Impact of drivers and challenges in 2022 and 2027
Exhibits111: Overview on Criticality of inputs and Factors of differentiation
Exhibits112: Overview on factors of disruption
Exhibits113: Impact of key risks on business
Exhibits114: Vendors covered
Exhibits115: Matrix on vendor position and classification
Exhibits116: AbbVie Inc. – Overview
Exhibits117: AbbVie Inc. – Product / Service
Exhibits118: AbbVie Inc. – Key news
Exhibits119: AbbVie Inc. – Key offerings
Exhibits120: Aldeyra Therapeutics Inc. – Overview
Exhibits121: Aldeyra Therapeutics Inc. – Product / Service
Exhibits122: Aldeyra Therapeutics Inc. – Key offerings
Exhibits123: Bausch Health Co Inc. – Overview
Exhibits124: Bausch Health Co Inc. – Business segments
Exhibits125: Bausch Health Co Inc. – Key news
Exhibits126: Bausch Health Co Inc. – Key offerings
Exhibits127: Bausch Health Co Inc. – Segment focus
Exhibits128: Bayer AG – Overview
Exhibits129: Bayer AG – Business segments
Exhibits130: Bayer AG – Key news
Exhibits131: Bayer AG – Key offerings
Exhibits132: Bayer AG – Segment focus
Exhibits133: F. Hoffmann La Roche Ltd. – Overview
Exhibits134: F. Hoffmann La Roche Ltd. – Business segments
Exhibits135: F. Hoffmann La Roche Ltd. – Key news
Exhibits136: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits137: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits138: Novartis AG – Overview
Exhibits139: Novartis AG – Business segments
Exhibits140: Novartis AG – Key offerings
Exhibits141: Novartis AG – Segment focus
Exhibits142: Ocular Therapeutix Inc. – Overview
Exhibits143: Ocular Therapeutix Inc. – Product / Service
Exhibits144: Ocular Therapeutix Inc. – Key offerings
Exhibits145: Otsuka Pharmaceutical Co. Ltd. – Overview
Exhibits146: Otsuka Pharmaceutical Co. Ltd. – Product / Service
Exhibits147: Otsuka Pharmaceutical Co. Ltd. – Key offerings
Exhibits148: Oxurion NV – Overview
Exhibits149: Oxurion NV – Product / Service
Exhibits150: Oxurion NV – Key offerings
Exhibits151: Pfizer Inc. – Overview
Exhibits152: Pfizer Inc. – Product / Service
Exhibits153: Pfizer Inc. – Key news
Exhibits154: Pfizer Inc. – Key offerings
Exhibits155: Regeneron Pharmaceuticals Inc. – Overview
Exhibits156: Regeneron Pharmaceuticals Inc. – Product / Service
Exhibits157: Regeneron Pharmaceuticals Inc. – Key offerings
Exhibits158: Santen Pharmaceutical Co. Ltd. – Overview
Exhibits159: Santen Pharmaceutical Co. Ltd. – Product / Service
Exhibits160: Santen Pharmaceutical Co. Ltd. – Key offerings
Exhibits161: Sun Pharmaceutical Industries Ltd. – Overview
Exhibits162: Sun Pharmaceutical Industries Ltd. – Product / Service
Exhibits163: Sun Pharmaceutical Industries Ltd. – Key offerings
Exhibits164: Teva Pharmaceutical Industries Ltd. – Overview
Exhibits165: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibits166: Teva Pharmaceutical Industries Ltd. – Key news
Exhibits167: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibits168: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibits169: Visufarma – Overview
Exhibits170: Visufarma – Product / Service
Exhibits171: Visufarma – Key offerings
Exhibits172: Inclusions checklist
Exhibits173: Exclusions checklist
Exhibits174: Currency conversion rates for US$
Exhibits175: Research methodology
Exhibits176: Validation techniques employed for market sizing
Exhibits177: Information sources
Exhibits178: List of abbreviations



★調査レポート[世界の眼科治療薬市場2023年-2027年] (コード:IRTNTR40882-23)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の眼科治療薬市場2023年-2027年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆